Skip to main content
 

Events

The National Institutes of Health (NIH) campuses host a variety of events that inform, challenge, and unite the biomedical research community. IRP investigators lead or participate in many of these events, and they regularly present their work at scientific conferences at the NIH and around the world. We invite you to learn about (and possibly join us in) some of our upcoming events. Unless otherwise noted, times listed are Eastern Standard Time (EST).

Wednesday, June 29, 2016, 12:00 pm to 1:00 pm

Lipsett Amphitheater, NIH Clinical Center (Bldg 10)

Dr. Nuria Carrillo, MD, Staff Clinician, Human Biochemical Genetics Section, NHGRI, will present “Developing Therapies for GNE Myopathy: The Importance of Natural History Studies” and Dr. Paul Kruszka, Staff Clinician, Medical Genetics Branch, NHGRI, will speak on “Sub-Saharan Africa and the Genetic Basis of Congenital Heart Disease.”

Go online for more information about Clinical Center Grand Rounds, http://clinicalcenter.nih.gov/about/news/grcurrent.html. The lecture will be videocast and can be viewed at http://videocast.nih.gov.

Reasonable Accommodations: Sign language interpreters will be provided. Individuals with disabilities who need reasonable accommodation to participate in this event should contact Clinical Center Communications at 301-496-0080. TTY users, please call through the Federal Relay Service at 1-800-877-8339.

 

Wednesday, June 29, 2016, 3:00 pm to 4:00 pm (reception to follow)

Masur Auditorium, NIH Clinical Center (Bldg 10)

Join us for the final 2015-2016 WALS, “MicroRNAs and their regulatory effects” by David Bartel, Ph.D., Professor of Biology and Geobiology at the Whitehead Institute.

From the speaker: “My laboratory has studied the ability of RNAs to catalyze reactions and more recently has focused on RNAs that regulate gene expression. MicroRNAs (miRNAs) are short RNAs that pair to sites within messenger RNAs (mRNAs) to down-regulate the expression of protein-coding genes. These mMiRNAs play critical roles in mammalian biology and disease. Indeed, because miRNAs specify the repression of most human genes, it is hard to find a disease, developmental process, or physiological state that is not influenced in some way by miRNAs. For this lecture, I will present an overview of miRNAs and their regulatory roles. I will then describe the molecular consequences of miRNAs on their mRNA targets and how these consequences change as the relationship between mRNA poly(A)-tail length and translational efficiency shifts during the early embryonic development.”

Come join your colleagues, DDIR Michael Gottesman and NIH Director Francis Collins at these top-notch lectures, even if you think they are outside of your area of interest. The Wednesday Afternoon Lecture Series is this highest-profile scientific lecture series at the NIH, created to keep the NIH community informed of the latest world-class science. Speakers are nominated by NIH scientific staff. Receptions with the speaker supported by our lecture partner, FAES, follow each lecture. This is the final talk for the 2015–2016 season. WALS will return in September. Check the WALS website later this summer for the 2016–2017 schedule, at http://oir.nih.gov/wals

Thursday, July 14, 2016, 12:00 pm to 1:30 pm

Room A1/A2, NIH Neuroscience Building, 6001 Executive Boulevard, Rockville MD

The Biomarkers in Pediatric Therapeutics announces next lecture in the biomarker module of the Sumner J. Yaffe Lecture Series, titled “Pediatric Pharmacodynamics Biomarkers Coming of Age,” presented by Dr. Sander Vinks of Cincinnati Children’s Hospital Medical Center, and Dr. Edmund Capparelli of University of California, San Diego. For more information, such as speaker bios, refer to http://bit.ly/28NgJRF.

Abstract: “Pediatric pharmacodynamics is the study of age-related maturation of the structure and activity of biologic systems and their effects on response of children to pharmacotherapy. Despite continued efforts by regulatory agencies and the pediatric drug research community to increase the availability of age-group-specific pharmacokinetic information there is a lack of pediatric efficacy, tolerability, and safety data for a large number of drugs. An important missing element in many pediatric pharmacometrics analyses is a mechanism-based link to pharmacodynamic endpoints to quantitatively describe the dose-expose-response relationship across the pediatric age spectrum. The development of a well worked paradigm for pharmacodynamic studies in neonates and children will require a similar effort in the area of population pharmacodynamics as we have seen in recent years with population pharmacokinetics studies. This lecture will address the factors responsible for the paucity of studies on pharmacodynamics and biomarkers and will discuss new strategies to better understand differences and similarities between adults, children and neonates to improve pediatric studies and therapies.”

Friday, July 15, 2016, 1:00 pm to 2:00 pm

Masur Auditorium, NIH Clinical Center (Bldg 10)

This year’s John W. Daly Memorial Lecture is “Marine Microorganisms Provide Access to New Drug Targets for the Treatment of Cancer” by William Fenical, Ph.D., Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography. Daly was a noted natural products chemist and pharmacologist in NIDDK who died in 2008. Please read more about John in the NIH Record and in a tribute in the journal Heterocycles.

Abstract: Marine microorganisms, and in particular marine actinomycete bacteria, are a genetically-unique and chemically-rich source for the discovery of new drug leads. The development of novel isolation and culture methods has allowed access to a variety of previously uncultured strains that now form the foundation for innovative cancer drug discovery efforts. Examining this new chemical source and coupling it with a program to identify new intracellular protein targets has provided several new and unpredicted pathways that can be exploited for cancer treatment. Cytotoxic marine microbial metabolites such as the ammosamides, marinopyrroles, napyradiomycins, and more recently the seriniquinones, show binding affinity to a diversity of new protein targets, illustrating that new approaches exist to treating various cancers. These and more recent discoveries will form the content of this presentation.

Thursday, September 8, 2016 to Friday, September 9, 2016

Room 620/630, Bldg 35, NIH Bethesda Campus

Join us for the 4th NCI-Pancreatic Cancer Symposium. This year’s theme is “Current Advances and Future Challenges in Research and Treatment.” Pancreatic cancer remains one of the most lethal malignancies, and is expected to be the second leading cause of death due to cancer by 2020 in the United States. Recent progress in the basic and translational research has identified molecular subgroups, critical pathways associated with disease aggressiveness and novel molecular targets that could be harnessed in improving survival in patients with pancreatic cancer. This symposium presents recent advances in our understanding of the development, progression, early detection and treatment of pancreatic cancer, and would provide an exciting forum to discuss the current advances and challenges in improving diagnosis, prevention and treatment of this lethal malignancy. Registration is free but seating is limited, so please register at https://ncifrederick.cancer.gov/events/PancreaticCancer2016/default.asp.